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Available online 10 February 2016The Genea090 human embryonic stem cell line was derived from a donated, fully commercially consented ART
blastocyst, carrying Htt gene CAG expansion of 45 repeats, indicative of Huntington Disease. Following ICM out-
growth on inactivatedhuman feeders, karyotypewas conﬁrmed as46, XXbyCGHand STR analysis demonstrated
a female allele pattern. The hESC line had pluripotent cell morphology, 91% of cells expressed Nanog, 95% Oct4,
90% Tra1–60 and 100% SSEA4 and gave a pluritest pluripotency score of 30.91, novelty of 1.23. The cell line
was negative for Mycoplasma and visible contamination.
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).(Resource tableName of stem cell lineDGenea090 — Huntington Disease affected
(Alternate ID: SIVF090)stitution Genea Biocells
Sterson who created resource Biljana Dumevskaontact person and email biljana.dumevska@geneabiocells.com
Siate archived/stock date June, 2012rigin Human embryos
pe of resource Derived human embryonic stem cell line
b-type HD affected human pluripotent cell line
ey marker expression Nanog, Oct4, Tra1–60, and SSEA4
uthentication Identity and purity of cell line conﬁrmed (Fig. 1
and Tables 1—2 below)
nk to related literature
(direct URL links and full
references)(McQuade & Balachandran, 2014)
http://www.ncbi.nlm.nih.gov/pubmed/25316320formation in public
databasesNational Institutes of Health registered, NIH:
NIHhESC-14-0245
UK Stem Cell Bank registered, UKSCB: SCSC14-49thical approval Obtained from the Genea Ethics Committee on 13
September 2005 under the Australian National
Health and Medical Research Council (NHMRC)
licence 309710Resource detailsDate of
derivationMay 2012aryotype 46, XX
x Female
luripotent YES — by Nanog, Oct4, Tra1–60, and SSEA4 staining and
pluritest. This is an open access article under thcontinued)Date of
derivatione CC BY-NC-ND licMay 2012isease status Expansion of CAG repeats (45 CAG repeats) — Huntington
Disease (HD) affected, OMIM: 143100erility The cell line is tested and found negative for Mycoplasma and
any visible contaminationbling lines
availableYES — Genea089 (XX, HD affected — NIH: NIHhESC-14-0247),
Genea091 (XX, HD affected — NIH: NIHhESC-14-0246)Materials and methods
Cell line derivation
The zona pellucida of a blastocyst-stage human embryo was manu-
ally removed using a small blade. The embryo was bisected and
plated onto irradiated human feeders (Detroit 551 HFF — 90,000/well
in 4-well) in 20% KSR medium with 20 ng/mL FGF added fresh (Amit
et al., 2000). CGH karyotyping and STR proﬁling were performed at
the ﬁrst cryobanking step from ICM outgrowths maintained on feeders.
Cells were then enzymatically passaged as single cells inM2 pluripotent
cell maintenance medium (Genea Biocells) and CGH/karyotyping was
repeated, immunoﬂuorescent pluripotent marker staining, pluritest
and sterility testing were performed.
Genetic analysis
1. Comparative Genomic Hybridisation (CGH) based chromosomal
analysis: Passage 4; CGH was used to screen targeted regions of the
genome for gains and losses associated with chromosomal imbal-
ances such as aneuploidy, deletions and duplications. CGH wasense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
CGH analysis summary; Genea090 (passage 4) reporting a female cell line and no abnor-
malities detected.
CGH summary
Sample name Genea090p4
Date reported 16th August 2012
Hybridisation
balance
Balanced hybridization was observed for all chromosomes,
relative to reference DNA
Copy number change No copy number changes above 400 kb were detected
Interpretation Female cell line — no abnormalities detected
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were scanned with the Agilent Scanner C and analysed using
Genomic Workbench Standard Edition 5.0 software (Agilent
Technologies).
2. DNA Proﬁling: Passage 4; DNA ‘ﬁngerprinting’ was performed using
the AmpFLSTR Identiﬁler PCR Ampliﬁcation Kit (Applied Biosystems
#4322288) to provide permanent genetic identiﬁcation of the
cell lines. https://www.thermoﬁsher.com/order/catalog/product/
4322288
Pluripotency assessment
1. Immunoﬂuorescence: Passage 8 (6 on feeders, 2 enzymatic); cells
were ﬁxed with formalin and stained with Nanog #560,483 1:200;
Oct4 #560,217 1:150: Tra1–60 #560121 1:150; SSEA4 #560308
1:200 (all BD Pharmingen). Images were acquired with an IN Cell
Analyser 6000 and quantiﬁed using In Cell Developer Software (GE).
2. Pluritest: Passage 8 (6 on feeders, 2 enzymatic); RNA was collected
and subjected to a Pluritest, a bioinformatic assay of pluripotency in
human cells based on gene expression proﬁles (Müller et al., 2012)Table 2
STR proﬁle; Genea090 (passage 4) demonstrating female allele pattern.
D8S1179 D21S11 D7S820 CSF1PO D3S1358 TH01 D13S31
GENEA090p4 13,15 29,30 11,12 10,12 17,18 6,9 8,11
Fig. 1. Pluripotency validation of Genea090. A) Immunoﬂuorescent staining (10×) of pluripoten
enzymatic). B) Quantitation of expression of pluripotentmarkers. C) Pluritest pluripotency (left
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the weSterility testing
1. Mycoplasma: Passage 8 (5 on feeders, 3 enzymatic); testing was per-
formed as per manufacturer's instructions using the MycoAlert My-
coplasma Detection Kit from LONZA
2. Microbial contamination: testing was performed in conjunction with
our QC measures. Cells were thawed and cultured in 7 mL antibiotic
free medium (Genea Biocells M2 medium) for 2–3 days at 37 °C. A
clear solution at ~48–72 h indicated lack of bacterial, fungal or
yeast contamination. Clarity of the solution was assessed by Cell Pro-
duction Team.
Veriﬁcation and authentication
Ethics/consents
Ethics approval for the project (‘Derivation of human embryonic
stem cells from embryos identiﬁed through pre-implantation genetic
diagnosis to be affected by known genetic conditions’) was obtained
from the Genea Ethics Committee on 13 September 2005. Excess ART
embryoswere fully consented for stem cell derivation by all responsible
people through an informed consent process (signed de-identiﬁed con-
sent form can be provided upon request). Donors have received no pay-
ment or ﬁnancial beneﬁts for their donation. Genea090 has been
derived from a donated, fully commercially consented embryo, original-
ly created by assisted reproduction technology (ART) for the purpose of
procreation. The embryo was identiﬁed through pre-implantation ge-
netic diagnosis to be affected by a genetic mutation and was declared
excess to reproductive needs. Derivation was performed under the
Australian National Health and Medical Research Council (NHMRC) li-
cence 309710. This licence was issued to GENEA on 7 May 2007. More
information about the licence can be obtained from the NHMRC7 D16S539 D2S1338 D19S433 vWA TPOX D18S51 D5S818 FGA
11,12 17,19 12,13 18,19 8,11 14 10,11 23
t cellmarkers SSEA4 (green), Nanog (red), Oct3/4 (green) and Tra1/60 (red), (passage 8, 2
) and novelty (right) scoreswith Genea090 (passage 8, 2 enzymatic) outlined in black. (For
b version of this article.)
521B. Dumevska et al. / Stem Cell Research 16 (2016) 519–521webpage at http://www.nhmrc.gov.au/health-ethics/human-embryos-
and-cloning/database-licences-authorising-use-excess-art-embryos
PGD analysis conclusion
Mutation; expansion of CAG (45 CAG repeats) in HTT gene. Family
tree; Father has 41 repeats; b inherited from his Father. Huntington
Disease (HD) affected.
Morphology
The derived stem cell line, Genea090, morphologically displays ad-
herent monolayer of compact cells in well-deﬁned colonies with high
nuclear to cytoplasmic ratio and prominent nucleoli.
Genetic analysis
The cell line has been karyotyped and tested by CGH, which demon-
strated 46, XX karyotype (Table 1, Supplementary Fig. 1) consistent
with original derivation and pre-implantation genetic diagnosis
(PGD). Analysis of STR markers showed allele pattern consistent with
female genotype (Table 2, Supplementary Fig. 2).
Pluripotency
GENEA090 is pluripotent by;
1. Immunoﬂuorescence with 91% Nanog positive, 95% Oct4, 90% Tra1–
60 and 100% SSEA4 positive (Fig. 1A, quantiﬁed in 1B).2. Pluritest with a pluripotency score of 30.91 and novelty score of 1.23
(Fig. 1C).Sterility
The cell line is tested and found negative for Mycoplasma and any
visible contamination (Supplementary Fig. 3).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2016.02.024.
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